SUNSHINE BIOPHARMA INC (SBFM) Fundamental Analysis & Valuation

NASDAQ:SBFM • US8677817004

Current stock price

1.1 USD
-0.01 (-0.9%)
At close:
1.1 USD
0 (0%)
After Hours:

This SBFM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SBFM Profitability Analysis

1.1 Basic Checks

  • In the past year SBFM has reported negative net income.
  • SBFM had a negative operating cash flow in the past year.
  • SBFM had negative earnings in each of the past 5 years.
  • SBFM had a negative operating cash flow in each of the past 5 years.
SBFM Yearly Net Income VS EBIT VS OCF VS FCFSBFM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a decent Return On Assets value of -19.03%, SBFM is doing good in the industry, outperforming 76.83% of the companies in the same industry.
  • The Return On Equity of SBFM (-24.76%) is better than 78.76% of its industry peers.
Industry RankSector Rank
ROA -19.03%
ROE -24.76%
ROIC N/A
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SBFM Yearly ROA, ROE, ROICSBFM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K 6K

1.3 Margins

  • The Gross Margin of SBFM (33.01%) is better than 72.97% of its industry peers.
  • In the last couple of years the Gross Margin of SBFM has declined.
  • SBFM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
SBFM Yearly Profit, Operating, Gross MarginsSBFM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SBFM Health Analysis

2.1 Basic Checks

  • SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SBFM has more shares outstanding
  • SBFM has more shares outstanding than it did 5 years ago.
  • SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SBFM Yearly Shares OutstandingSBFM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SBFM Yearly Total Debt VS Total AssetsSBFM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • SBFM has an Altman-Z score of -1.31. This is a bad value and indicates that SBFM is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.31, SBFM is in line with its industry, outperforming 53.09% of the companies in the same industry.
  • SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.31
ROIC/WACCN/A
WACC8.92%
SBFM Yearly LT Debt VS Equity VS FCFSBFM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • SBFM has a Current Ratio of 4.20. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
  • SBFM has a Current ratio of 4.20. This is comparable to the rest of the industry: SBFM outperforms 49.61% of its industry peers.
  • SBFM has a Quick Ratio of 2.09. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.09, SBFM is not doing good in the industry: 73.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 2.09
SBFM Yearly Current Assets VS Current LiabilitesSBFM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SBFM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 88.82% over the past year.
  • The Revenue has grown by 13.24% in the past year. This is quite good.
  • SBFM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 340.61% yearly.
EPS 1Y (TTM)88.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
Revenue 1Y (TTM)13.24%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%11.64%

3.2 Future

  • Based on estimates for the next years, SBFM will show a very strong growth in Earnings Per Share. The EPS will grow by 41.20% on average per year.
  • Based on estimates for the next years, SBFM will show a quite strong growth in Revenue. The Revenue will grow by 15.04% on average per year.
EPS Next Y98.01%
EPS Next 2Y41.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.21%
Revenue Next 2Y15.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SBFM Yearly Revenue VS EstimatesSBFM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
SBFM Yearly EPS VS EstimatesSBFM Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

1

4. SBFM Valuation Analysis

4.1 Price/Earnings Ratio

  • SBFM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SBFM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SBFM Price Earnings VS Forward Price EarningsSBFM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SBFM Per share dataSBFM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SBFM's earnings are expected to grow with 41.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.2%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SBFM Dividend Analysis

5.1 Amount

  • SBFM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SBFM Fundamentals: All Metrics, Ratios and Statistics

SUNSHINE BIOPHARMA INC

NASDAQ:SBFM (3/13/2026, 8:00:02 PM)

After market: 1.1 0 (0%)

1.1

-0.01 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners5.24%
Inst Owner Change-49.21%
Ins Owners0%
Ins Owner Change0%
Market Cap5.40M
Revenue(TTM)37.32M
Net Income(TTM)-5.99M
Analysts82.86
Price Target6.12 (456.36%)
Short Float %4.8%
Short Ratio5.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-145.44%
Min EPS beat(2)-247.59%
Max EPS beat(2)-43.29%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.23%
Min Revenue beat(2)-17.63%
Max Revenue beat(2)-16.82%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-51.88
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS7.6
BVpS4.93
TBVpS4.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.03%
ROE -24.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.01%
FCFM N/A
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
F-Score3
Asset Turnover1.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 299.16%
Cap/Sales 2.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 2.09
Altman-Z -1.31
F-Score3
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)874.71%
Cap/Depr(5y)526.53%
Cap/Sales(3y)5.32%
Cap/Sales(5y)3.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
EPS Next Y98.01%
EPS Next 2Y41.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.24%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%11.64%
Revenue Next Year-0.21%
Revenue Next 2Y15.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.52%
OCF growth 3YN/A
OCF growth 5YN/A

SUNSHINE BIOPHARMA INC / SBFM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SUNSHINE BIOPHARMA INC?

ChartMill assigns a fundamental rating of 4 / 10 to SBFM.


Can you provide the valuation status for SUNSHINE BIOPHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to SUNSHINE BIOPHARMA INC (SBFM). This can be considered as Overvalued.


How profitable is SUNSHINE BIOPHARMA INC (SBFM) stock?

SUNSHINE BIOPHARMA INC (SBFM) has a profitability rating of 2 / 10.